The premise for this investigative study was grounded in the necessity to ensure astronaut health and safety during extended missions beyond Earth. Recognizing that drug degradation could jeopardize mission outcomes, SwRI researchers adopted a methodical approach to measure how repackaging impacts the chemical integrity of pharmaceuticals. Without deploying the medications into orbit, the team simulated high-stress environmental conditions akin to those potentially encountered during space transit—exposing samples to sustained high temperature (40 degrees Celsius) and elevated humidity (75 percent relative humidity).

Initial quantitative analyses revealed alarming results. Within a mere two months, the active pharmaceutical ingredient (API) in a widely used antibiotic sample deteriorated to undetectable levels when stored in zip-style plastic bags, while other drugs exhibited significant reductions in their active components. These findings underscore the vulnerability of repackaged medications that may be subjected to harsh environmental factors, a scenario highly likely in the constrained and variable microclimates within spacecraft or lunar habitats.

Employing advanced analytical techniques, including high-performance liquid chromatography (HPLC), scientists continually monitored the concentration of drug molecules over a six-month period. This technique provided precise quantification of the APIs, affording robust data on the kinetics of degradation. While the experiment was Earth-based and did not incorporate the complex variables present in actual spaceflight—such as exposure to cosmic radiation or microgravity—the observed degradation trends signal serious concerns about the long-term viability of medications stored outside their controlled packaging.

The implications for space medicine are profound. Presently, NASA’s strategy of repackaging arises from strict spatial constraints aboard spacecraft, necessitating compact storage solutions to maximize payload efficiency. However, the research suggests a reevaluation of this strategy might be imperative, where preserving pharmaceutical efficacy could demand advancements in packaging technology or the development of more resilient drug formulations tailored for extraterrestrial environments.

This investigation also resonates with terrestrial pharmaceutical handling practices. Many patients and healthcare providers routinely transfer medications into alternative containers for convenience or organization, unaware of the potential for accelerated degradation. The SwRI findings illuminate the broader necessity for strict adherence to recommended storage guidelines, especially for medications intended for extended use or storage under non-ideal conditions.

Dr. Judy Herrera, a senior research scientist at SwRI, who led the study, emphasized the criticality of this issue: “Our data demonstrate that medication stability can be compromised significantly by common repackaging practices. While our focus was on spaceflight, these findings have ramifications for anyone managing medications over prolonged durations under non-ideal storage environments.”

Beyond the immediate findings, SwRI’s pharmaceutical and bioengineering divisions bring a comprehensive capacity to address multifaceted challenges in drug development and stability assessments. Under Darrel Johnston’s direction, the facility integrates drug discovery, analytical chemistry, and formulation expertise, enabling rapid and innovative responses to unconventional problems, such as those posed by space medicine.

NASA’s ambitious Artemis missions set unprecedented timelines and conditions for human space exploration. Long-duration habitation on the Moon will confront astronauts with environmental stressors ranging from radiation to variable thermal cycles, all of which could influence drug longevity and performance. Future research inspired by the SwRI findings will likely employ simulated space conditions, including vacuum environments and radiation exposure, to better predict pharmaceutical behavior during actual missions.

SwRI’s inquiry serves as a call to action for developing robust, space-adapted pharmaceutical storage protocols. Potential strategies may include advanced blister packs with superior barrier properties, lyophilized (freeze-dried) formulations with enhanced shelf-life, or even in-situ pharmaceutical manufacturing aboard spacecraft to bypass degradation concerns entirely.

Moreover, this research highlights the intricate relationship between environmental chemistry and pharmaceutical shelf-life. Factors like humidity and temperature not only catalyze degradation pathways but can also affect molecular conformations and the physical state of drug compounds, leading to reduced bioavailability and efficacy. Understanding these degradation mechanisms at a molecular level will be essential in crafting medicines fit for the cosmos.

As Artemis marches forward toward establishing humanity’s foothold on the Moon, ensuring the reliability and safety of medication will be a cornerstone concern. The pioneering work by SwRI sets a scientific foundation for ongoing efforts to safeguard astronaut health and supports the broader vision of sustainable human presence in deep space exploration.

For more detailed information on pharmaceutical research and development in space flight, Southwest Research Institute offers extensive resources and ongoing updates at their biomedical and pharmaceutical development programs.

Subject of Research: Pharmaceutical stability and degradation in repackaged medications under simulated spaceflight environmental conditions.

Article Title: Investigating the Degradation of Repackaged Medications: Ensuring Drug Stability for Extended Space Missions.

News Publication Date: June 2, 2026

Web References: https://www.swri.org/markets/biomedical-health/pharmaceutical-development?&utm_medium=referral&utm_source=eurekalert!&utm_campaign=pharma-in-space-pr

Image Credits: Southwest Research Institute

Keywords

Pharmaceutical stability, medication degradation, spaceflight medicine, drug repackaging, high-performance liquid chromatography, Artemis program, lunar habitation, biomedical research, Southwest Research Institute, drug formulation, space environmental simulation, astronaut health.

This revolutionary system hinges on a uniquely modified mannequin embedded with a meticulously crafted 3D-printed cardiovascular model. The simulator replicates the human heart’s anatomy with impressive precision, complete with authentic heart valves, artificial blood vessels, and a fluid-filled circulatory loop mimicking the actual hemodynamics of blood flow. By testing this model under both Earth-like gravity and reduced gravity scenarios, the team has successfully confirmed the replication of physiological blood pressure patterns akin to those observed during effective CPR on Earth, while uncovering significant differences in cardiovascular responses caused by hypogravity.

The lead author, Zoé Lord, a PhD candidate at Queen’s University and an alumnus of Concordia University, highlights that “the simulator exhibited increased systolic, diastolic, mean arterial pressure, and pulse pressure under hypogravity conditions compared to Earth gravity.” These findings underscore the model’s high fidelity and its capacity to provide invaluable insight into cardiovascular function during prolonged exposure to space environments, thereby facilitating the development of effective medical protocols for deep space expeditions.

Traditional CPR techniques have been adapted primarily through superficial strategies focused on external performance metrics such as compression depth and rate. However, these parameters alone fall short of gauging whether sufficient blood volume circulates through vital organs—a critical determinant of successful resuscitation. In microgravity or hypogravity environments where bodily fluids distribute differently and physical bracing is challenging, CPR methods effective on Earth may fail to generate adequate perfusion.

The Concordia team’s simulator addresses this knowledge gap by integrating internal physiological measurements into CPR evaluation. According to Professor Lyes Kadem, director of the Laboratory of Cardiovascular Fluid Dynamics, their approach “shifts the focus from health provider techniques to patient-centered hemodynamic responses.” This perspective marks a revolutionary step in space medicine, providing a quantitative framework to assess and refine life support strategies based on realtime vascular data.

To replicate hypogravity, experiments were conducted not only within Concordia’s controlled laboratories but also aboard a Canadian government-operated Falcon 20 jet outfitted for space science experiments. During parabolic flights—brief intervals when gravity is substantially reduced—the simulator administered cardiac compressions to the artificial heart model, simulating CPR under space-analog conditions. Sensors positioned along critical pathways such as the carotid artery captured pressure metrics indicative of fluid propulsion to the brain, enabling objective assessment of CPR efficacy mid-flight.

Christian Andrade, a current Concordia undergraduate and member of the research team, played a vital role in live data collection and interpretation throughout the microgravity tests. This hands-on experience during dynamic flight stress-testing ensured that observations were rooted in authentic physiological scenarios rather than simulations alone, thereby enhancing the robustness and credibility of their findings.

Despite the simulator’s sophisticated initial design, its developers emphasize that it represents only the beginning of a series of increasingly complex models. Future iterations aim to incorporate a more anatomically complete skeletal framework—including a spine and rib cage—along with a nuanced thoracic cavity to better mimic the compressive mechanics experienced during real CPR. Such enhancements are crucial because human cardiac geometry changes in microgravity; the heart notably shrinks, altering the mechanics and efficacy of compressions.

Moreover, refining the artificial vascular pathways and improving sensor instrumentation remain a high priority. These improvements will facilitate a deeper understanding of the subtle interplay between mechanical forces and biological responses under diverse gravitational conditions. Ultimately, the research team envisions deploying their advanced mannequin aboard the International Space Station, where in situ measurements during actual spaceflight will afford unmatched insights into human cardiovascular resilience and emergency care protocols beyond Earth.

Beyond its immediate applications for space exploration, this research stands to transform terrestrial resuscitation science by yielding novel data on hemodynamic interactions during CPR. The high-fidelity simulator’s capacity to dissect internal pressure dynamics provides a powerful tool to optimize emergency cardiac care across various clinical contexts. Additionally, the study exemplifies how computational modeling married with experimental flight conditions can push the boundaries of biomedical research and personalized medicine.

This innovative research was generously funded by the National Research Council of Canada, reflecting a growing national commitment to advancing space medicine and biotechnology. The study’s results were recently published in the prestigious journal npj Microgravity, marking a significant milestone in the scientific community’s understanding of human physiology in space.

The full research article, titled “A high-fidelity simulator for evaluation of hemodynamic response during cardiopulmonary resuscitation in hypogravity environments,” is accessible through Nature’s publication platform, providing detailed methodology, experimental data, and comprehensive analysis. This breakthrough study lays the foundation for future explorations aimed at safeguarding human life as humanity embarks on its most ambitious voyages beyond our home planet.

Subject of Research: People

Article Title: A high-fidelity simulator for evaluation of hemodynamic response during cardiopulmonary resuscitation in hypogravity environments

News Publication Date: 25-Feb-2026

Web References:
https://www.nature.com/articles/s41526-026-00577-1

References:
Lord, Z.V., Andrade, C., and Kadem, L., et al. (2026). A high-fidelity simulator for evaluation of hemodynamic response during cardiopulmonary resuscitation in hypogravity environments. npj Microgravity. DOI: 10.1038/s41526-026-00577-1

Image Credits: Zoe Lord

Keywords

space medicine, hypogravity, cardiopulmonary resuscitation, CPR, cardiovascular simulation, hemodynamics, blood flow, parabolic flights, space health, artificial heart model, 3D-printed cardiovascular system, aerospace biomedical engineering

Bone health is critically compromised during space missions, leading to serious challenges for astronaut safety and mission success. Microgravity has long been observed to disrupt the delicate balance of bone remodeling, tipping the scale toward bone resorption and loss. However, while the clinical manifestations are well documented, the underlying cellular mechanisms remained elusive until now. The study places mitochondrial quality control via mitophagy—an autophagic process that clears damaged mitochondria—at the heart of osteogenic dysfunction induced by SMG.

The investigative team employed an innovative rotary cell culture system to emulate the effects of microgravity on cultured osteoblasts. This setup enabled precise modeling of the mechanical unloading conditions experienced in space, allowing researchers to monitor cellular proliferation, differentiation, and apoptosis in a controlled laboratory environment. To quantify these processes, assays including CCK-8 for proliferation, flow cytometry for apoptosis, and enzymatic staining for osteogenic markers were meticulously performed, revealing a stark suppression of osteoblast function under SMG.

Mitochondrial health was probed through a battery of complementary techniques. The study measured ATP production, which serves as a fundamental indicator of cellular energy status, alongside reactive oxygen species (ROS) levels that signify oxidative stress. They utilized JC-1 staining to assess mitochondrial membrane potential, a sensitive measure of mitochondrial integrity, and electron microscopy provided ultrastructural insight into mitochondrial morphology. The results were compelling – SMG induced mitochondrial swelling and disrupted cristae architecture, hallmarks of organelle dysfunction.

Central to the study’s novelty is the focus on mitophagy, specifically the PINK1/Parkin pathway, which orchestrates the removal of damaged mitochondria. Gene and protein expression analyses via qPCR and Western blot demonstrated a marked downregulation of mitophagy markers under simulated microgravity conditions. This suppression implies a failure in mitochondrial quality control mechanisms, leading to the accumulation of dysfunctional mitochondria within osteoblasts, thereby impairing their vitality and function.

In an exciting advance, the researchers explored the therapeutic potential of icariin (ICA), a small molecule known to influence mitochondrial function. Treating SMG-exposed osteoblasts with ICA partially restored mitochondrial parameters, including membrane potential and ATP content, and reactivated mitophagy markers such as PINK1 and Parkin. This intervention also ameliorated osteogenic marker expression and improved cell viability, demonstrating that targeting mitochondrial health could reverse some aspects of microgravity-induced bone cell dysfunction.

This study compellingly argues that defective mitophagy is a pivotal contributor to the osteogenic deficits observed under unloading conditions. Impaired clearance of damaged mitochondria not only compromises cellular bioenergetics but also enhances oxidative stress, driving apoptosis and halting the differentiation necessary for bone formation. Consequently, mitophagy emerges as a promising therapeutic target to mitigate bone loss not only in astronauts but potentially in patients suffering from immobilization-related osteoporosis or other mechanical unloading scenarios.

The research brings mitochondrial dynamics into sharper focus as central players in skeletal biology, particularly under atypical mechanical environments. The detailed mechanistic insights it provides help bridge the gap between observed physiological outcomes and intracellular events. Understanding how mitophagy impairment interplays with osteoblast dysfunction could pave the way for novel drug development strategies designed to sustain bone health in challenging conditions.

Moreover, the partial rescue by icariin underscores the value of small molecules in regulating mitochondrial quality control pathways. As a natural compound derived from Epimedium species, icariin has garnered attention for its multi-faceted bioactivity—including antioxidant, anti-inflammatory, and now mitophagy-modulating properties. Its functional restoration of mitochondrial integrity and osteogenic capacity under simulated microgravity highlights its translational potential for clinical applications.

Beyond its implications for space medicine, this study offers broader biomedical relevance. Bone loss due to disuse, aging, and disease shares mechanistic overlaps with microgravity-induced skeletal deterioration. Thus, insights into mitophagy and mitochondrial function could inform treatments for osteoporosis and other metabolic bone diseases affecting millions worldwide. The intersection of mitochondrial biology and bone metabolism is poised to become a fertile ground for future research and therapeutic innovation.

In summary, this pioneering investigation elucidates how simulated microgravity suppresses osteoblast function by impairing mitophagy and mitochondrial health. Through rigorous experimentation, the authors demonstrate that maintaining mitochondrial quality control via the PINK1/Parkin pathway is essential for osteoblast proliferation, differentiation, and survival. Their findings spotlight icariin as a promising candidate to counteract these deleterious effects, suggesting a roadmap for mitigating unloading-induced bone loss and enhancing astronaut health on long-duration missions.

As humanity prepares for extended space exploration, the burden of bone loss remains a critical hurdle. Studies such as this provide vital molecular clues and actionable targets, bringing us closer to effective countermeasures. Ensuring astronaut skeletal integrity will be crucial not only for physical health but also for mission success and future interplanetary colonization. This research marks an important step forward, demonstrating that by protecting the mitochondria, we may protect the bones—and ultimately, the explorers who rely on them.

Subject of Research: Osteoblast dysfunction and mitochondrial quality control under simulated microgravity
Article Title: Osteoblast dysfunction associated with mitophagy suppression under simulated microgravity
Article References: Xue, J., Wang, M., Liu, S. et al. Osteoblast dysfunction associated with mitophagy suppression under simulated microgravity. BioMed Eng OnLine 24, 113 (2025). https://doi.org/10.1186/s12938-025-01454-w
Image Credits: AI Generated
DOI: https://doi.org/10.1186/s12938-025-01454-w